Tags Posts tagged with "Inc."


0 724
Marijuana-Stocks -Cannabis-road

Although the Canadian medical marijuana suppliers are larger, Medical Marijuana, Inc. (NASDAQOTH: MJNA) is the largest U.S. marijuana stock right now. This excludes a few larger biotech companies dealing with the development of cannabinoid drugs. Medical Marijuana, Inc. has a market cap of slightly less than $300 million which is surprising in an industry where the annual revenue is projected to hit somewhere in the $50 billion range within the next ten years.

The only answer to this is that the marijuana industry is getting ready for bigger companies to step forward and claim their place; and who better for the job than the tobacco giants such as: Altria Group (NYSE: MO), Philip Morris (NYSE:PM), and Reynolds American (NYSE: RAI). So, is there a major change coming to the medical marijuana industry with big tobacco entering the scene?

Will Marijuana Stocks Make Their Own Path?

In the 1960s and 70s rumors floated around stating that the major tobacco companies were considering going into the marijuana market and that some were trademarking brand names for their potential marijuana products. The rumors led to many denials by the companies themselves and that put the idea to rest for a short amount of time.

On April 1, 2016, the website Abril Uno published an article titled “Philip Morris Introduces Marlboro ‘M’ Marijuana Cigarettes.” The article stated that “the company has been high on the idea of marketing cannabis, and has been monitoring it for some time.” As the name of website translates to ‘April first’, this had been an interesting April Fools’ Joke despite the serious possibility of it occurring.

The overlap possibilities between the tobacco companies and medical marijuana industries are large with some big tobacco companies even entering the vaping market. In 2014, Altria acquired the e-vapor business of Green Smoke for $110 million. In 2013, Reynolds launched its e-cigarette brand named Vuse.

Now yes, that’s not the same thing as entering the marijuana market, but when looking at the numbers for projections in the industry, it only makes sense that there is a place staked out for the large tobacco companies. In the next ten to fifteen years, we may see a large jump in the medical marijuana industry done by big tobacco entering the scene.

0 1167

Currently, there is a lack of standardization in regards to strain definition and identification for cannabis. Most people buying cannabis, for retail or wholesale, make their decisions largely dependent on the name of the stain they are purchasing. Therefore, this creates an issue as there are no widely accepted and scientifically backed agreements for classification of cannabis strains. Buyers are left making their decisions without any true knowledge of what they are getting. An independent cannabis testing and media firm, Digipath, Inc. supports the industry’s practices for dependable testing and delivers cannabis news coverage and education about the industry.

They are comprised of two business units, Digipath Labs, and TNM News Corp. Digipath Labs is attempting to set the industry standard for testing all forms of cannabis-based products. They plan to use patented standard operating procedures to ensure product safety and efficacy with FDA-compliant laboratory equipment. TNM News Corp. has founded a news network focused on cannabis, The National Marijuana News, that delivers education, interviews, and news on all things cannabis. Digipath, Inc. has a vision for establishing a classification of cannabis strains based on science and not their names. The Chief Science Officer for Digipath, Inc., Dr. Cindy Orser, Ph.D., plans to use its large cache of cannabis chemotypical data to bring a market solution to these unaddressed issues in genotype stratification.

The company is aware that the lack of standardized naming conventions in the industry is making it harder to know what is on the market to make effective comparisons. This issue is impacting many things such as confidence at the dispensary in knowing what you are buying, and regulatory problems in terms of trademarking and patenting strains. Due to these issues, people are forced to pay a premium to know that their flower has been authenticated to know that they will obtain the desired experience. A large amount of cannabis testing labs are complying with the minimum state-mandated quality assurance testing protocols as well as basic chemoprofiling of cannabis and related products.

Digipath Labs has decided to start a multivariate analysis with over 4,000 chemoprofiles from flower samples in attempts to authenticate the flower. The company expects to consolidate the unique flower chemoprofiles to approximately 25-30 chemotypes with shared cannabinoid-to-terpene values. These chemoprofiles will be influential in defining clinically relevant chemotypes hiding behind an excess of strain names. These efforts by the company will help buyers understand what they are actually buying and bring to light what is hidden beneath the pseudonyms given to so many cultivars. This company will allow consumers to be more confident at dispensaries and allow other companies to trademark and patent strains.

0 1741
VPR Brands

We wanted to share this press release with everyone since the #PotStock craze is in full swing, especially with the elections on Tuesday. VPRB has an interesting story because of one glaring factor. That factor being it recently acquired the entire asset base of Vapor Corp (VPCO) in August of this year. VPCO has/had annual revenues around $4,000,000, and also up-listed to the Nasdaq in 2014.

Unfortunately shortly before the up-listing the management team left the company it built up and Vapor Corp’s new team decided to make heavy investments into brick and mortar vape shops, which did not go well for them. As many companies put into a bind have done, they took on very bad toxic debt. Despite the fact that the business was still generating revenue, the publicly traded stock never recovered and it became an acquisition target. 

So here’s why this is interesting: The person that built this company before its epic fall is the CEO of VPRB. The company has zero toxic debt, is tightly held and clearly knows the business. This is a story that we’ve been following and we encourage everyone to read the shareholder update we’ve been waiting for. 

FT LAUDERDALE, FL / ACCESSWIRE / November 3, 2016 / VPR Brands, LP (VPRB) on behalf of the company, I am pleased to give our shareholders a 90-day corporate update regarding the recent acquisition of the wholesale operations and assets of Vapor Corp (VPCO). We are excited to inform our shareholders that the transition of our management and business operations are proceeding on schedule. The Companys wholesale division, along with current product lines have never stopped generating revenue since we took over. The transition has been seamless and this is partly due to the fact that we kept many of the former employees and sales associates on board, while strategically lowering costs by eliminating corporate redundancies and creating a business culture that is efficient and fiscally responsible.

On the corporate side, it is important to note that VPRB has no toxic debt. The company has a very low float of 2,343,816 and is widely held by insiders and management. Under my previous management we were able to uplist Vapor Corp from pink sheets all the way to the Nasdaq in 2014 just prior to my departure. Our management is again focused on building shareholder value while increasing sales and profit margins on our product lines.

The current brands under management are:

HoneyStick brand (vapehoneystick.com) a premium open tank mod specifically designed and intended to be used for essential oils and which is becoming popular in medical and recreational marijuana legal states.

Vaporin brand (vaporin.com) is a high quality entry-level range of product sold nationwide in smoke shops, convenience stores and gas stations.

VaporX brand (iVaporX.com) a premium mod and open tank system program for the experienced Vape customer all for under $100 and available at retail in custom display.

Hookah Stix brand Hookah flavor inspired cigalikes (which are electronic cigarettes designed to look as much as a tobacco cigarette as possible).

Helium brand (vapehelium.com) the very first eliquid to be sold chilled to stay fresh in its unique customer counter top display chiller.

With regards to the legal Medical and Recreational cannabis markets we have heavy market penetration in California, Colorado, Oregon, Connecticut, and Minnesota as well as service and have accounts in Washington, Nevada, Michigan, New Mexico, Alaska, , Vermont‎, and Illinois.

Our products are sold in dispensaries with both private label and our flagship Honeystick brand. The Company has aligned with key partners in the states whether on the extraction or distribution side to service dispensaries within each market. We will be providing further updates on these partnerships, but expect our Co-branded items to be rolled into the market in Q4 2016.

As stated previously we are fully operational at the original Vapor Corp offices and warehouse‎ located at 3001 Griffin Rd, in Ft Lauderdale FL and have even negotiated a reduction in our monthly facility rent by 30% per month. The core team employed in the wholesale operation of Vapor Corp. have been integrated into VPR Brands, LP (VPRB) assuming similar roles in sales and logistics. This is important as it will preserve continuity in the business allowing for the preservation of current customer relationships. Additional continuity is being preserved because all the brands, trademarks, websites and customer accounts were also transferred over to VPR Brands. Integration has been going smoothly and the wholesale and distributor accounts are pleased to have original Vapor Corp management back‎ at the helm.

Vapor Corp name recognition, existing relationships with both suppliers and customers since 2008 is one of the longest running in the industry and is invaluable to VPR Brands, LP (VPRB). Vapor Corp has previously sold to over 25 of the countrys largest distributors and retail chain store customer and has existing vendor # ‘s with these accounts. It is our goal to reignite our business relationships with all the previous customers who helped make our products the most widely recognized in the industry. Under my previous management (of Vapor corp) sales peaked close to $25 million in 2014.

Although Vapor Corp was once among the strongest in the industry, previously reported revenues for their wholesale business dropped from a reported$1,889,777 in the first quarter of 2016 by approximately $520,000 to a reported $1,369,415 for the 2nd quarter ending Jul 31, 2016. Considering the acquisition of the Vapor Corp wholesale business occurred at the end of July 2016, VPR Brands will report only two months of acquired wholesale business in this coming 3rd quarter 2016. Prior to the acquisition, VPR Brands previously reported $61,526 in revenue for the 2nd quarter related to sales of its Helium brand e-liquid.

The timing of the acquisition of Vapor Corps wholesale business was also very important. Within the E-cigarette and vapor industry significant upheaval is occurring due to a change in regulatory treatment by the FDA of these products. The government had set August 8, 2016 as the cutoff date of any new product from being introduced at retail in the U.S. without first receiving premarket approval from the FDA. It is expected this provision will allow for products that were currently available prior to August 8, 2016 to remain in the marketplace likely through 2019. Considering that no new products are being allowed to come into the marketplace, current wholesalers, such as VPR Brands, are especially well-positioned to provide product to retailers and consumers via online assets.

There is a massive shift occurring in the market for electronic cigarettes and other related products. Where several years ago the major use of electronic cigarettes was as a replacement for traditional cigarettes, the prevalence of using electronic cigarette technologies for the consumption of cannabis is quickly sweeping the marketplace. Whether for traditional tobacco product use or as a delivery mechanism for either medical or recreational cannabis usage, there is simply no debate about the sheer size of this market and the growth the market has experienced. We are positioned to be a large part of this industry.


Kevin Frija CEO
VPR Brands, LP.

    1 11526

    FBEC Worldwide, Inc. CEO Reduces Salary by 50% to Reinvest Capital into Production

     FBEC Worldwide, Inc. (FBEC), a beverage company with intellectual property formulas and marketing capability for the production and distribution of proprietary beverages and CBD products, today announced the CEO has reduced his salary by 50%. CEO Jason Spatafora has cut his own salary to $7,500 per month down from $15,000 per month. The additional $7,500 per month in working capital will be used to ramp up production.

    The Company is receiving excellent feedback from retailers currently selling the WolfShot™ Hemp Energy™ shot. Additional working capital will prove beneficial as strong demand for the product requires an increase in production. The Company is also seeing heavy interest for products recently added to their portfolio such as the DuBe® hemp energy shot and Mά brand CBD vaporizer.

    It has always been the Company’s plan to initiate a limited product rollout gathering feedback from retailers and consumers to help conserve capital early on. Now, with a boosted and diversified product portfolio, the Company has enough data to efficiently ramp up production. The increase will help satisfy certain supply requirements in order to meet demand.

    CEO Jason Spatafora said, “We have come an extraordinary way in a short amount of time with FBEC Worldwide Inc.’s product portfolio and partnerships. As we begin to scale our operations to truly make this a national lifestyle brand, we have to allocate funds accordingly to meet agreed upon measures related to demand and production to make this possible.”

    Spatafora added, “In the last week, we have greatly improved our capital structure and today’s news represents an internal milestone for the Company.”

    About FBEC Worldwide, Inc.

    FBEC Worldwide is an innovative beverage company dedicated to offering proprietary products focused towards significant target markets, both domestic and abroad. We are committed to increasing our market size and scope through the optics of creative marketing and most importantly customer satisfaction. Our growth strategies will focus on a number of major initiatives including, unique branding opportunities that will be targeted at key demographic groups, and to develop strong community and distributor relationships.

    As we look ahead, FBEC Worldwide will develop and build name brands focused on strong rates of growth within key fundamental consumer groups. Our company is dedicated to becoming a leading developer of name brand beverage alternatives geared specifically towards large, significantly important demographics within major markets.

    Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.


    Joe Sirianni
    MIDAM Ventures LLC
    (305) 707-7018

    SOURCE: FBEC Worldwide, Inc.

    0 1987

    NEW YORK, Oct. 9, 2014 (GLOBE NEWSWIRE) — Tauriga Sciences, Inc. (TAUG), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, has today announced the completion of a $600,000 USD equity private placement with select institutional and accredited individual investors. The pricing of this equity private placement was at $0.0125 per share and there were no warrants offered in conjunction with this financing. The shares issued pursuant to this private placement are “restricted securities” as defined by Rule 144 of the Securities Act of 1933, as amended.

    The proceeds from this financing will be used for working capital purposes, specifically to grow revenues in the natural wellness businesses and advance the commercialization efforts of Pilus Energy’s synthetic biology technology platform for industrial wastewater remediation and value creation. Pilus Energy LLC (“Pilus Energy”), is a wholly owned subsidiary of Tauriga Sciences, Inc.

    The Company is pleased to disclose that Tokyo, Japan based Dragoon Capital Inc. (through its affiliated investors) has thus far invested $350,000 USD in private placement capital. On August 25, 2014, Tauriga announced the execution of an Investment Banking Agreement with Dragoon Capital Inc. (“Dragoon Capital”). In addition Dragoon Capital has invited Tauriga’s Chairman & CEO, Dr. Stella M. Sung and Chief Medical Officer, Lawrence A. May, M.D. to Japan from October 10-15 for a multi-city investor presentation.

    Also of note, three members of Tauriga’s management team and a successful industry colleague participated in this above-mentioned private placement financing. Tauriga’s Chairman & CEO, Dr. Stella M. Sung, Tauriga’s Chief Medical Officer, Lawrence A. May, M.D., and Tauriga’s Vice President Strategic Planning each participated, as did Mr. Derek A. Peterson, Founder and CEO of Terra Tech Corp. (TRTC).

    About Tauriga Sciences, Inc.:

    Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com.

    About Dragoon Capital, Inc.

    Dragoon Capital Inc. is an independent investment banking firm that provides advice to institutional investors and middle-market and emerging growth companies in Japan and worldwide. Together, the firm’s management professionals have more than 80 years of experience providing private and public companies with a broad spectrum of investment banking and financial advisory services, including: mergers and acquisitions; equity and debt capital raises; and restructurings. The firm provides objective, unbiased, results-focused services that clients need to achieve their goals. For more information, please visit:http://www.dragoon.co.jp/en/index.html


    This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.


    Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

    Tauriga Sciences, Inc.:
    Dr. Stella M. Sung,
    Chairman and Chief Executive Officer
    Tauriga Sciences, Inc.
    San Diego: + 1-858-353-5749
    Montreal: + 1-514-840-3697
    Email: ssung@tauriga.com

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements